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ABSTRACT
We selected 19 significantly-mutated genes in AMLs, including FLT3, DNMT3A, 
NPM1, TET2, RUNX1, CEBPA, WT1, IDH1, IDH2, NRAS, ASXL1, SETD2, PTPN11, TP53, 
KIT, JAK2, KRAS, BRAF and CBL, and performed massively parallel sequencing for 114 
patients with acute myeloid leukemias, mainly including those with normal karyotypes 
(CN-AML). More than 80% of patients had at least one mutation in the genes tested. 
DNMT3A mutation was significantly associated with adverse outcome in addition to 
conventional risk stratification such as the European LeukemiaNet (ELN) classification. 
We observed clinical usefulness of mutation testing on multiple target genes and the 
association with disease subgroups, clinical features and prognosis in AMLs.
INTRODUCTION
Acute myeloid leukemia (AML) is a biologically 
heterogeneous disease and its clinical behaviors largely 
vary among different cases. Prognostic stratification in 
AML is important to determine treatment strategy. A 
well-proven prognostic factor is cytogenetic abnormality, 
according to which patients can be categorized as 
favorable, intermediate and unfavorable cytogenetic groups 
[1, 2]. Those with inv(16)/t(16;16), t(8;21) and t(15;17) are 
classified into favorable cytogenetic risk group while those 
with complex karyotype, t(6;9), inv(3)/t(3;3), -5/del(5q) 
and -7/del(7q) are classified into adverse cytogenetic risk 
group. Cases with intermediate cytogenetic risk group are 
predominantly with normal cytogenetics (CN-AMLs), 
constituting about 50% of all AML cases.
Recently, mutations in FLT3, NPM1 and CEBPA 
have been shown to have significant prognostic impact 
were suggested to be included in the risk stratification 
system by European LeukemiaNet (ELN) [2]. In addition, 
several studies have suggested prognostic implication 
of mutations in other genes. DNMT3A mutations (about 
one third of intermediate cytogenetic risk group) were 
suggested to be associated with adverse outcomes among 
intermediate-risk cytogenetic group [3]. IDH1/2, which 
encodes the enzyme isocitrate dehydrogenase, was 
recently shown to be mutated in about 16% of all AMLs 
and have significant prognostic impact in CN-AML with 
mutated NPM1 without FLT3-ITD [4]. In some studies, 
TET2 mutation was suggested to be associated with 
poor prognostic impact in CN-AML or intermediate 
cytogenetic risk group [5, 6]. KIT mutation was suggested 
to have adverse prognostic impact in AML with t(8;21) 
or inv(16)/t(16;16) [7]. WT1 mutation in AML was found 
about 10-15% and associated with adverse prognostic 
impact in some studies [8, 9]. TP53 mutation is frequently 
associated with therapy-related myeloid neoplasm with 
adverse prognostic impact [10, 11]. RUNX1 was found 
~20% of de novo CN-AML with short overall survival 
and relapse free survival [11]. ASXL1, SETD2, JAK2, 
KRAS, PTPN11, NRAS, BRAF and CBL were found in 
AML and other myeloproliferative neoplasms such as 
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myelodysplastic syndrome/myeloproliferative neoplasm 
(MDS/MPN) with varying frequency and prognostic 
impact [12–14].
In the present study, we have comprehensively 
reviewed recent literatures on AML mutations and selected 
target genes which show relatively high frequencies 
(NPM1, FLT3, IDH1/2, CEBPA, DNMT3A, WT1), adverse 
prognostic impact (TET2, ASXL1, NRAS, KRAS, KIT) 
and associations with secondary/therapy related myeloid 
neoplasm/cytogenetic abnormalities (JAK2, TP53, 
PTPN11, BRAF, CBL, SETD2) [5, 12, 14–22]. And we 
investigated mutation profiles of these 19 genes selected 
genes [5, 12, 14–22] and their association with clinical 
parameters and outcomes in Korean patients with AML. 
Our data suggested a significant impact of DNMT3A 
mutations over other conventional prognostic factors. 
Investigation on a relatively homogeneous population 
from a single institute will provide valuable information to 
the current knowledge on the impact of gene mutations on 
AMLs, together with molecular epidemiological insights 
on this regional population.
RESULTS
Clinical characteristics of 114 AML cases
Demographics and clinical characteristics 
of enrolled cases are summarized in Table 1 and 
Supplementary Table S1. Seventy male and 44 female 
were enrolled. Ninety-eight adult patients (>19 years) and 
16 childhood (<20 years) AML patients were enrolled. 
Ninety-three cases were de novo AMLs and 12 cases 
were secondary or relapsed AMLs. Two cases were 
secondary AMLs evolved from primary myelofibrosis and 
polycythemia vera.
Categorization and cytogenetic risk group
Of the 114 patients enrolled, 11 had missing or 
inconclusive cytogenetic results. Among the 103 cases 
with unequivocal cytogenetic information, 77 were CN-
AMLs and 26 were cytogenetically abnormal AMLs 
(CA-AMLs). As to recurrent cytogenetics, four cases with 
t(8;21)(q22;q22), 2 cases with inv(16)(p13q22) and 2 
cases with t(15;17)(q22;q21) were also enrolled.
When categorized by the 2008 WHO classification 
of hematologic malignancies [23], AML-MRC was 
the most common type (43/114, 37.7 %). AML with 
maturation (20/52), AML without maturation (10/52) 
and acute myelomonocytic leukemia (10/52) were most 
common in AML-NOS.
According to the ELN prognostic stratification 
[2], eight patients were categorized into favorable, 84 
patients were into intermediate, and 11 patients were 
into unfavorable cytogenetic risk groups. Among the 43 
AML-MRC cases, 13 cases had cytogenetic abnormalities. 
Among these, 12 cases including those with -5/del(5q), 
-7/del(7q) and complex cytogenetic abnormalities were 
categorized as poor cytogenetic risk group according to 
the ELN prognostic stratification.
Information on treatment
Information on treatment regimen was available 
in 89 adult AML cases. A total of 74 patients received 
the intensive chemotherapy (high dose cytarabine and 
idarubicin). Nine patients had received low intensity 
chemotherapy (hydroxyurea, decitabine, azacitidine 
etc.), and six patients did not receive chemotherapy 
due to early death or unstable clinical status. Among 43 
AML-MRC patients, 28 (73.6%) had received intensive 
chemotherapy, and 5 (13.2%) received low intensity 
chemotherapy. Five AML-MRC patients (13.2%) did not 
receive chemotherapy.
Among 56 intermediated risk group (i.e. de novo 
CN-AML with other than mutated NPM1 without 
FLT3-ITD) patients, 46 (81.2%) had received intensive 
chemotherapy, and 6 (10.7%) received low intensity 
chemotherapy. Four AML-MRC patients (7.1%) did not 
receive chemotherapy.
Mutation spectra, hotspots and co-occurrence
The overall fold coverage (read length/number of 
reads) was over 1000× (range: 1030-4830×) in all target 
regions except for some focal regions in KRAS, CEBPA 
and TET2 (Supplementary Figure S1). Among the 199 
variations called and filtered, 166 (83.4%) were confirmed 
by Sanger sequencing (Supplementary Table S2 and S3). 
Because 3′-part of CEBPA was sequenced with very low 
coverage, Sanger sequencing results were integrated 
as a supplementation. The detection rate of FLT3-ITD 
by massively parallel sequencing was low (9 of 34 
positive cases), especially in those with low mutant allele 
proportion, so clinical testing results were also integrated.
As a total, ninety-two (80.7%) cases had at least one 
mutation in the 19 genes investigated, suggesting that this 
panel could be used effectively as initial workup of AMLs. 
For all confirmed mutations, we statistically analyzed 
mutation profiles according to clinical and cytogenetic 
subgroups (Figure 1 and 2).
In CN-AML, FLT3-ITD was the most common 
mutation (36.4%), followed by NPM1 and DNMT3A 
mutations (29.9% and 22.1%, respectively). As previously 
reported, NPM1 mutations were found only in CN-AML 
and the majority (19/24, 79.2%) was type A (960insTCTG) 
mutation, while three Type B (960insCATG) and two Type 
D (960insCCTG) mutations were identified. DNMT3A 
mutations were found only in CN-AML, with R882H 
mutation being most common (9/20, 45%) as previously 
reported and other mutations being scattered across 
proline-tryptophan rich, zinc finger and methytransferase 
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domains (Supplementary Figure S2). RUNX1 mutations 
were found in 13 cases (15 variation) with frameshift 
being the most predominant mutation type (10/15, 66.6%) 
(Supplementary Figure S3). WT1 mutations were detected 
in 13 cases (11.4%) overall, especially in codons 381 
and 382 on exon 7 (Supplementary Figure S4). TET2 
mutations were distributed throughout coding regions, 
and loss-of-function mutations including nonsense 
Table 1: Clinical and cytogenetic characteristics of enrolled cases
CN-AML 
(n=77)
CA-AML 
(n=26)
Unknown* 
(n=11)
Total
Male/Female 48/29 16/10 6/5 70/44
Age, years (mean±SD) 51.4±19.3 40.8±25.6 61.7±15.5 50.0±21.2
Complete remission 60/63(95.2%) 20/21(95.2%) 2/2(100%) 82/86(95.3%)
Relapse 27/60(45.0%) 9/20(45.0%) 1/2(50%) 37/82(45.1%)
Bone marrow transplantation 35/77(45.5%) 14/26(53.8%) 2/2(100%) 51/105(48.6%)
Age group
 1-19 years 7 9 16
 20-39 years 10 1 1 12
 40-59 years 29 8 3 40
 ≥60 31 8 7 46
Secondary or relapse 4 8 12
De novo 73 18 2 93
2008 WHO classification
 AML with t(8;21)(q22;q22) 4 4
 AML with inv(16)(p13q22) 2 2
 AML with t(15;17)(q22;q21) 2† 2
 AML with myelodysplasia-related changes 30 13 43
 AML, not otherwise specified
  AML with minimal differentiation(M0) 4 1 5
  AML without maturation(M1) 8 2 10
  AML with maturation(M2) 20 0 20
  Acute myelomonocytic leukemia(M4) 9 1 10
  A cute monoblastic/monocytic 
leukemia(M5) 2 1 3
  Acute erythroid leukemia(M6) 2 2
  Acute megakaryoblastic leukemia(M7) 2 0 2
  Unknown* 11 11
 Cytogenetic risk group
  Favorable 0 8 8
  Intermediate 77 7 84
  Unfavorable 11 11
  Unknown* 11 11
* Cytogenetic results were unavailable or inconclusive
† One patient had normal karyotype but fluorescence in situ hybridization and reverse transcript PCR for PML-RARA 
rearrangement were positive
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Figure 1: Mutational profiles of AML cases analyzed. A. Mutation frequencies according to chromosome abnormalities. B. 
Mutation status in individual cases and co-occurrence among other mutations and chromosome abnormalities. Gray-color box indicates 
mutated case. For cytogenetic abnormalities, Black-color box indicates CN-AML, Gray-color box indicates CA-AML, White-color box 
indicates other AML (i.e. unknown cytogenetics).
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(9/17) and frameshift (5/17) were commonly observed 
(Supplementary Figure S5). All IDH1 mutations detected 
were R132C (100%, 9/9), and IDH2 mutations were 
detected either as R140Q (60%, 6/10) or R172K (30%, 
3/10). NRAS mutations were detected in 10 cases (7.9%) 
overall and all were missense mutations in codons 12, 
13 and 61 (Supplementary Figure S6). ASXL1 mutations 
were clustered around 5′-part of exon 12 (Supplementary 
Figure S7). PTPN11 mutations were found in 4 cases 
(3.5%) overall, with a predominant occurrence in exon 3 
(Supplementary Figure S8). KIT mutations were detected 
only in two cases; AML with t(8;21) and AML-MRC. 
TP53 mutations were detected in three cases with AML-
MRC.JAK2 V617F mutation was detected in secondary 
AMLs evolved from polycythemia vera and primary 
myelofibrosis, while one de novo AML (AML without 
maturation) case also harbored JAK2 V617F mutation. 
SETD2 mutations were detected in three (2.6%) de novo 
AMLs. Only one case with double CEBPA mutations was 
found in this study, whereas 9 cases had only a single 
CEBPA mutation. No mutation was detected in the CBL, 
KRAS and BRAF genes.
NPM1 mutations tended to co-occur with DNMT3A 
(P<0.001) and FLT3-ITD mutations (P<0.001) while 
DNMT3A mutation was frequently concurrent with 
IDH1/2 mutation (P=0.002) (Table 2). In line with 
several previous reports [24–28], high degrees of mutual 
exclusivity existed between IDH1 and IDH2, WT1 and 
IDH1/2, and DNMT3A and CEBPA mutations. We also 
newly observed a high exclusivity between DNMT3A and 
RUNX1 mutations.
Different mutation frequencies according to 
AML subgroups
FLT3-ITD mutations were frequently found in 
CN-AMLs than CA-AMLs (36.4% vs 11.5%; P=0.017) 
(Table 3). NPM1 mutations (29.9% vs. 0.0%; P=0.002) 
and DNMT3A mutations (22.1% vs. 0%; P=0.006) were 
exclusively found in CN-AML. FLT3-ITD, NPM1, 
DNMT3A, IDH1/2, TET2, WT1 and RUNX1 mutations 
were relatively common in de novo AMLs, while RUNX1, 
NRAS, PTPN11, JAK2, WT1 and IDH1/2 mutations were 
so in secondary or relapsed AMLs (Table 3). Nonetheless, 
only JAK2 mutation showed statistical significance.
Among the cases with no recurrent cytogenetic 
abnormalities according to the 2008 WHO 
Classification, 92.3% (48/52) of AML, not otherwise 
specified (AML-NOS) and 81.4% (35/43) of AML-
MRC had at least one mutations in the 19 genes 
examined (Table 4).NRAS mutation was more frequent 
in AML-MRC (16.3% vs. 3.8%, P=.074), whereas 
Figure 2: Mutation spectrums according to the 2008 WHO Classification. Proportion of mutations in each gene according to 
AML subgroups.
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Table 2: Co-occurrence of gene mutations
NPM1 NPM1
DNMT3A 
wild mutant P
FLT3-ITD
wild mutant P
wild 81 13 <.001 wild 71 9 <.001
mutant 9 11 mutant 19 15
FLT3-ITD WT1
DNMT3A
wild mutant P
IDH1/2
wild mutant P
wild 70 24 .003 wild 84 13 .211
mutant 10 10 mutant 17 0
CEBPA IDH1/2
DNMT3A
wild mutant P
TET2
wild mutant P
wild 84 10 .204 wild 86 16 0.690
mutant 21 0 mutant 11 1
IDH1/2 RUNX1
DNMT3A
wild mutant P
ASXL1
wild mutant P
wild 85 9 .002 wild 95 10 .066
mutant 12 8 mutant 6 3
RUNX1 IDH1
DNMT3A 
wild mutant P
IDH2
wild mutant P
wild 82 12 .459 wild 97 7 .532
mutant 19 1 mutant 9 1
Table 3: Mutation profile according to cytogenetic abnormality and de novo and secondary/relapsed cases
Gene CN-AML 
(n=77)
CA-AML(n=26) P De novo (n=93) Secondary or 
relapsed (n=12)
P
ASXL1 6(7.8%) 3(11.5 %) .689 8(8.6%) 1(8.3%) 1.000
BRAF 0(0.0%) 0(0.0 %) - 0(0.0%) 0(0.0%) -
CBL 0(0.0%) 0(0.0 %) 0(0.0%) 0(0.0%) -
CEBPA 9(11.7%) 1(3.8 %) .445 10(10.8%) 0(0.0%) .600
DNMT3A 17(22.1%) 0(0.0 %) .006 17(18.3%) 0(0.0%) .208
FLT3-ITD 28(36.4%) 3(11.5 %) .017 31(33.3%) 1(8.3%) .101
FLT3-TKD 4(5.2%) 1(3.8 %) 1.000 5(5.4%) 0(0.0%) 1.000
IDH1 7(9.1%) 1(3.8 %) .676 7(7.5%) 1(8.3%) 1.000
IDH2 8(10.4%) 2(7.7 %) 1.000 9(9.7%) 1(8.3%) 1.000
JAK2 3(3.9%) 0(0.0 %) .570 1(1.1%) 2(16.7%) .034
KIT 0(0.0%) 2(7.7 %) .062 1(1.1%) 1(8.3%) .216
KRAS 0(0.0%) 0(0.0 %) - 0(0.0%) 0(0.0%) -
NPM1 23(29.9%) 0(0.0 %) .002 23(24.7%) 0(0.0%) .064
NRAS 6(7.8%) 3(11.5 %) .689 6(6.5%) 3(25.0%) .065
(continued )
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TET2 mutation was less frequent in AML-MRC than 
AML-NOS (2.3% vs. 19.2%, P=.011). Similar with 
previous reports [10, 29], we observed a relatively high 
frequency of TP53 mutations in AML-MRC (0.0% vs. 
7.1%, P=.089).
Complete remission and relapse rates according 
to mutation status
Complete remission (CR) rate was 95.3% (82/86) 
and relapse rate was 45.1% (37/82). RUNX1 mutation was 
Gene CN-AML 
(n=77)
CA-AML(n=26) P De novo (n=93) Secondary or 
relapsed (n=12)
P
PTPN11 3(3.9%) 1(3.8 %) 1.000 2(2.2%) 2(16.7%) .063
RUNX1 6(7.8%) 6(23.1 %) .070 9(9.7%) 3(25.0%) .138
SETD2 2(2.6%) 1(3.8 %) 1.000 3(3.2%) 0(0.0%) 1.000
TET2 11(14.3%) 0(0.0 %) .061 11(11.8%) 1(8.3%) 1.000
TP53 0(0.0%) 3(11.5 %) .015 2(2.2%) 1(8.3%) .308
WT1 9(11.7%) 4(15.4 %) .734 11(11.8%) 2(16.7%) .642
Table 4: Comparison of mutation profiles and clinical characteristics between AML-MRC and AML-NOS
AML-NOS(n=52) AML-MRC(n=43) P
Age 46.9±21.2 52.9±20.6 .112
Sex(male/female) 33/19 28/15 .867
Complete remission 44/46(95.7%) 28/30(94.7%) .645
Relapse 15/44(34.1%) 19/28(57.6%) .005
Bone marrow 
transplantation
29/52(55.8%) 15/43(34.9%) .042
Gene mutation
ASXL1 4(7.7%) 4(9.3%) 1.000
CEBPA 8(15.4%) 2(4.7%) .107
DNMT3A 10(19.2%) 7(16.3%) .709
FLT3-ITD 21(40.3%) 10(23.3%) .076
FLT3-TKD 4(7.7%) 0(0.0%) .124
IDH1 5(9.6%) 3(7.0%) .725
IDH2 3(5.8%) 6(16.3%) .177
NPM1 14(26.9%) 9(20.9%) .497
NRAS 2(3.8%) 7(16.3%) .074
PTPN11 1(1.9%) 3(9.3%) .325
RUNX1 6(11.5%) 6(14.0%) .764
SETD2 2(3.8%) 1(2.3%) 1.000
TET2 10(19.2%) 1(2.3%) .011
TP53 0(0.0%) 3(7.0%) .089
WT1 8(15.4%) 3(7.0%) .335
JAK2 2(3.8%) 1(2.3%) 1.000
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associated with low complete remission rate (57.1% vs. 
100%, P=.001). We observed that NRAS and DNMT3A 
mutations were associated with high relapse rates (41.7% 
vs. 100%, P=.037 for NRAS; 38.9%, vs. 80.0%, P=.034, 
for DNMT3A) in adult de novo AML (Supplementary 
Table S4).
Overall survival according to mutation status
We investigated overall survival (OS) according to 
mutation status in adult (>19 years) de novo AMLs with 
normal karyotype (n=66) or in intermediate cytogenetics 
risk group (n=68) and found that DNMT3A mutation was 
significantly associated with short OS in a multivariate cox 
regression model (Supplementary Table S5).
We further reclassified adult cases according to the 
ELN classification which incorporates FLT3-ITD, NPM1 
and CEBPA mutation status. DNMT3A and PTPN11 
mutation were associated with short OS in the favorable 
risk ELN group (i.e. de novo CN-AML with mutated 
NPM1 without FLT3-ITD or de novo CN-AML with 
doubly-mutated CEBPA, n=10) (Supplementary Figure S9). 
DNMT3A mutations were associated with short OS in 
intermediate risk group (i.e. de novo CN-AML with other 
than mutated NPM1 without FLT3-ITD, n=56) (Figure 3).
Relapse free survival according to mutation 
status
We also investigated relapse free survival (RFS) 
according to mutation status in 53 adult (>19 years) 
de novo CN-AML cases. In a multivariable cox regression 
model, only DNMT3A mutation was associated with 
short RFS (Supplementary Table S6). We observed the 
similar results in analysis of RFS in 55 adult (>19 years) 
de novo intermediate cytogenetic risk group AML cases 
(Supplementary Table S6). When re-grouped by the 
ELN classification, DNMT3A was associated with short 
RFS in the intermediate risk ELN group (Figure 4 and 
Supplementary Figure S10).
Clinical outcomes of adult de novo AML-MRC 
and AML-NOS
AML-MRC had significantly shorter RFS than 
AML-NOS, while OS was not significantly different 
(Supplementary Figure S11).
DISCUSSION
Considering the high prevalence of gene mutations 
in AML their prognostic impact and disease monitoring, 
mutation profiling at initial diagnosis may be necessary 
in addition to the conventional workups [4, 6, 30]. Recent 
high throughput sequencing technologies may be useful 
for detecting mutations in a number of target genes 
[19, 31, 32]. Compared to the whole genome or exome 
sequencing with highly sophiscated, time-consuming 
and intensive efforts, targeted gene sequencing may be 
a practical and ideal method for clinical testing in AML, 
with low cost, short turnaround time and less burden for 
Figure 3: Overall survival according to gene mutations in intermediate group (adult de novo CN-AML with other than 
mutated NPM1 without FLT3-ITD) according to the ELN classification.
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bioinformatics [31, 33, 34]. Through a custom targeted 
panel, we could detect most of the target sites with high 
fold coverages (>1,000) and more than 80% of cases had 
at least one mutation in the genes investigated, suggesting 
the targeted sequencing strategy could be useful for 
initial workup. However, we had suboptimal coverages 
for CEBPA, where guanine-cytosine (GC) content is high 
and PCR amplification is problematic, and FLT3-ITD 
region, where large tandem duplication is common and 
short amplicon sequencing can miss some mutations. 
So for such mutations, conventional Sanger sequencing 
or PCR-fragment length analysis may be needed as a 
supplement [35].
As a whole, we observed mutation frequencies 
similar to previous studies in Western countries [3, 6, 10, 
25, 27, 30] as well as in Asian countries. Wang et al [36] 
reported high mutation rates (>10%) in CEBPA, NPM1, 
DNMT3A, FLT3-ITD, NRAS, IDH2 and WT1. Kihara 
et al [37] reported high mutation rates of FLT3, NPM1, 
CEBPA, DNMT3A and KIT mutations in Japanese patients 
with AML. Some studies focusing on a single or a few 
genes have been reported in Korean patients with AML. 
DNMT3A R882 was detected 7.5% [38] and 18.3% [39] 
in Korean patients with CN-AML. Ahn et al reported 
that mutation rates for IDH1/2, TET2, NRAS and WT1 
were 16.5%, 8.7%, 6.1% and 14.8%, respectively, in 115 
Korean patients with CN-AML [39].
The impact of FLT3-ITD, NPM1 and CEBPA 
mutations on clinical outcome are well-established now, as 
implemented in the ELN classification [2, 28]. However, 
we observed particularly significant impact of DNMT3A 
mutations in the favorable or intermediate risk ELN 
group. As well, relapse rate of DNMT3A-mutated cases 
was significantly higher than unmutated cases (80.0% 
vs. 38.9%, P=0.034). Ahn et al [39] also reported poor 
prognostic impact (short OS, short RFS and high relapse 
rate) of DNMT3A R882 mutations in Korean patients with 
CN-AML after hematopoietic cell transplantation. Other 
previous studies also support that DNMT3A mutation can 
be an important prognostic factor [25, 26, 40–42] although 
some studies failed to find such associations [38, 43]. 
DNMT3A mutation was known to be more frequent in CN-
AMLs, and we surprisingly observed a high exclusivity of 
the mutations in CN-AMLs compared CA-AMLs (22.1% 
vs. 0%). This might be due to the small number of CA-
AMLs analyzed but should be further investigated in an 
extended set of patients. Considering the high positive 
rates and possible clinical implications, we may suggest 
that DNMT3A can be used in routine diagnostics and as 
an additional factor to the ELN risk stratification. We also 
observed possible prognostic implication of some genes 
with lower frequencies, including WT1, PTPN11, NRAS 
and ASXL1. Comprehensive mutation profiling may be 
needed when clinical implication of these rare mutations is 
established by future large studies and meta-analyses.(35)
In conclusion, we observed the recurrent mutation 
profile and their clinical significance using Korean 
AML patients. Although relatively small number of 
enrolled cases and heterogeneous population, it is first 
comprehensive mutation analysis using Korean patients. 
Figure 4: Relapse free survival according to gene mutations in intermediate group (adult de novo CN-AML with other 
than mutated NPM1 without FLT3-ITD) according to the ELN classification.
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Considering the wide heterogeneity in mutational 
spectrums and clinical characteristics, it will be essentially 
needed to accumulate more data on the mutational profile 
and clinical associations in AMLs from different centers 
and working groups.
MATERIALS AND METHODS
Study population
We obtained bone marrow samples from 114 
patients with AML diagnosed at Samsung Medical 
Center from 2008 to 2012, as well as peripheral blood 
samples from 4 healthy controls. Genomic DNA was 
isolated using the Wizard Genomic DNA Purification kit 
(Promega, Madison, WI, USA). Diagnosis are based on 
2008 WHO classification of tumors of haematopoietic 
and lymphoid tissues [23]. AML-MRC was defined as 
AML with morphological features of myelodysplasia or 
a prior history of a myelodysplastic syndrome (MDS) 
or myelodysplastic/myeloproliferative neoplasm (MDS.
MPN), or MDS-related cytogenetic abnormalities, and 
absence of the specific genetic abnormalities. AML-NOS 
were classified according to morphology, cytochemical 
statin and/or immunophenotypic results. Chromosome 
study was performed with a standard protocol and 
karyotypes were described according to the International 
System for Human Cytogenetic Nomenclature (ISCN) 
2009. The Institional Review Board at Samsung Medical 
Center approved the current study (IRB No. 2014-
05-016-002).
Targeted high-throughput sequencing
From a literature review, we selected 19 genes 
significantly mutated in AML [5, 12, 15, 16]]; they 
included FLT3-ITD, FLT3-TKD, DNMT3A, NPM1, 
TET2, RUNX1, CEBPA, WT1, IDH1, IDH2, NRAS, 
ASXL1, SETD2, PTPN11, TP53, KIT, JAK2, KRAS, 
BRAF and CBL (Supplementary Table S7).Custom target 
enrichment and amplicon library preparation was done 
using the Access Array System (Fluidigm, South San 
Francisco, CA, USA),[18] followed by massively parallel 
sequencing on the Miseq System (Illumina, San Diego, 
CA, USA) [44].
Analysis of high-throughput sequencing data
A schematic overview of bioinformatics analysis 
is presented in Supplementary Figure S12. After quality 
control by the SAMtool and fastQC softwares,(46) raw 
files were aligned to the human reference genome (build 
GRCh37) using the Burrows-Wheeler Aligner (BWA) 
with default parameters.(47) Local alignment was done 
with the Genome Analysis Toolkit (GATK), followed 
by variant calling by the GATK-Haplotype caller and 
Varscan algorithms.(48) Read depth and coverage were 
estimated using the BEDTools.(49) Called variants were 
annoatated using the SnpEff software(50) and filtered 
according to the following strategy; i) variation calls 
detected in normal healthy control were excluded, ii) only 
missense, nonsense, framshift, start gain and splice site 
mutations were included, iii) variations found over 0.1% 
of general population in public databases (NCBI dbSNP 
and ESP6000)(51) were excluded, iv) only variations with 
allele frequecy >20% in GATK-Haplotype caller and/
or Varscan were included, and v) variants were further 
filtered by visual inspection on Inegrative Genomics 
Viwer (IGV) [45]. SIFT and PolyPhen softwares [46, 47] 
were used for in-silico analysis of damaging effects of 
missense variations.
Crosscheck and validation by Sanger sequencing
Variants filtered by the strategy mentioned above 
were further confirmed by Sanger sequecing. For FLT3-
ITD, FLT3-TKD, JAK2 V617F, KIT, CEBPA and NPM1 
mutations, we integrated clinical testing results wherever 
available; all these were tested by Sanger sequencing and 
FLT3-ITD was double-checked by PCR and fluorescent 
fragment length analysis. Primers used for Sanger 
sequecing are summarized in Supplementary Table S8. 
Sequencing was performed using the BigDye Terminator 
Cycle Sequencing Ready Reaction Kit on an ABI Prism 
3730 Genetic Analyzer (Applied Biosystems, Foster 
City, CA, USA). The sequence data was analyzed using 
the Sequencher software (Gene Codes Corp., Ann Arbor, 
MI, USA).
Statistical analysis and clinical parameters
Statistical analysis was performed using the PASW 
Statistics 20.0 software (IBM, Armonk, NY, USA). 
Significance between categorical data was calculated by 
Chi-square or Fisher’s exact tests. Differences in survival 
between mutation groups were analyzed by Kaplan–Meier 
estimates. Multivariable Cox regression analysis was 
performed to examine the impact of mutations along with 
other clinical variables. OS was measured from the time 
from diagnosis to death or last follow-up. RFS was defined 
only for patients achieving CR, measured from the date 
of achievement of a remission until the date of relapse or 
death from CR, death or any cause. A P-value of <0.05 
was considered as statistically significant.
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